Study of Atropine Therapeutic Effect on Myopic Progression

• Aged 5 to 12 years at the time of consent
• Refractive error of SE at least -1.0 D and no greater than -8.0 D in both eyes as measured by cycloplegic autorefraction at visit 1 and visit 2.
• Confirmed myopia progression of 0.5D or more within past 1year
• Astigmatism of 2.5D or less in both eyes
• Distance Best Corrective Visual Acuity to logMAR 0.2 or better in both eyes at visit1.
• Normal IOP under 21mmHg in both eyes.
• Anisometropia of SE less than 2.0D as measured by cycloplegic autorefraction at visit 1.
• Written informed consent willingly obtained by both subject and his/her parents

Exclusion Criteria:

• Hypersensitivity to atropine or other cycloplegic agent.
• History of the surgery of refractive correction
• Having ocular disease affect to visual function or refractive error: history of glaucoma, macula r degeneration, diabetic eye disease, uveitis, etc, or presence of conjunctivitis at screening visit.
• Having systemic diseases that affect to vision loss
• Having risk of IOP elevation such as narrow angle, Shallow Anterior Chambers, etc
• Presence of binocular function disorder or stereopsis disorder
• Amblyopia or manifest strabismus
• History of premature birth(less than 37weeks) or low birth weight(less than 2,500g)
• Previous or current use of atropine or Ortho-K lens for myopia
• Down syndrome, spastic paralysis, brain damage, spastic palsy, bladder
• Presence of neurological diseases like epilepsy, etc. which could expect difficulties in compliant to the ocular examinations.
• Presence of clinically significant cardiac and respiratory diseases
• Participation in any other clinical study of an investigational product within 3-month prior to current IP administration.
• Based on the investigator's discretion, subject who is not proper to participate in the trial.